Loading…
Loading…
EQUITY / NASDAQ · XNCM
Revelation Biosciences Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.7636 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 0.7636 USD · Volume 43,908
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -3,662,241 USD | -2,461,229 USD | — |
| Net income | -3,323,384 USD | -2,444,382 USD | — |
| Cash and cash equivalents | 11,482,792 USD | — | — |
| Total liabilities | 2,430,946 USD | — | — |
| Total equity | 10,066,986 USD | 3,825,784 USD | +163.14% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 11,482,792 USD | — | — | 10,700,331 USD | 10,700,331 USD | 12,708,489 USD | — | — |
| Net incomeIncome statement | -3,323,384 USD | -6,332,435 USD | -3,009,051 USD | — | -8,913,649 USD | -1,907,176 USD | -6,402,643 USD | -2,444,382 USD |
| Operating profitIncome statement | -3,662,241 USD | -6,754,741 USD | — | — | -9,070,814 USD | -1,943,011 USD | -6,499,226 USD | -2,461,229 USD |
| Total assetsBalance sheet | 12,497,932 USD | — | — | 11,582,924 USD | 11,582,924 USD | 12,856,342 USD | — | — |
| Total equityBalance sheet | 10,066,986 USD | — | 12,988,953 USD | 8,860,995 USD | 8,860,995 USD | 11,001,835 USD | — | 3,825,784 USD |
| Total liabilitiesBalance sheet | 2,430,946 USD | — | — | 2,721,929 USD | 2,721,929 USD | 1,854,507 USD | — | — |
| Capital expendituresCash flow statement | — | 111,507 USD | — | — | — | — | — | — |
| Financing cash flowCash flow statement | — | 6,666,012 USD | — | — | 12,470,894 USD | — | 12,512,060 USD | — |
| Investing cash flowCash flow statement | — | -111,507 USD | — | — | — | — | — | — |
| Operating cash flowCash flow statement | — | -5,772,044 USD | — | — | -8,269,581 USD | — | -6,302,589 USD | — |
| Report source | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 02/26/2026 | Open report ↗ Published: 11/06/2025 | Open report ↗ Published: 11/06/2025 | Open report ↗ Published: 08/06/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.